JP7527785B2 - プロスタサイクリン類似体製剤 - Google Patents

プロスタサイクリン類似体製剤 Download PDF

Info

Publication number
JP7527785B2
JP7527785B2 JP2019514208A JP2019514208A JP7527785B2 JP 7527785 B2 JP7527785 B2 JP 7527785B2 JP 2019514208 A JP2019514208 A JP 2019514208A JP 2019514208 A JP2019514208 A JP 2019514208A JP 7527785 B2 JP7527785 B2 JP 7527785B2
Authority
JP
Japan
Prior art keywords
administration
preformulation
component
formulation
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529408A5 (enExample
JP2019529408A (ja
Inventor
チベルグ、フレドリック
バロウスカス、ユスタ
ニスター、カタリン
ジョンソン、マルクス
Original Assignee
カムルス エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615754.7A external-priority patent/GB201615754D0/en
Priority claimed from GBGB1621277.1A external-priority patent/GB201621277D0/en
Application filed by カムルス エービー filed Critical カムルス エービー
Publication of JP2019529408A publication Critical patent/JP2019529408A/ja
Publication of JP2019529408A5 publication Critical patent/JP2019529408A5/ja
Application granted granted Critical
Publication of JP7527785B2 publication Critical patent/JP7527785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019514208A 2016-09-15 2017-09-15 プロスタサイクリン類似体製剤 Active JP7527785B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1615754.7A GB201615754D0 (en) 2016-09-15 2016-09-15 Formulations
GB1615754.7 2016-09-15
GBGB1621277.1A GB201621277D0 (en) 2016-12-14 2016-12-14 Formulations
GB1621277.1 2016-12-14
PCT/EP2017/073359 WO2018050864A1 (en) 2016-09-15 2017-09-15 Prostacyclin analogue formulations

Publications (3)

Publication Number Publication Date
JP2019529408A JP2019529408A (ja) 2019-10-17
JP2019529408A5 JP2019529408A5 (enExample) 2020-10-22
JP7527785B2 true JP7527785B2 (ja) 2024-08-05

Family

ID=59887281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514208A Active JP7527785B2 (ja) 2016-09-15 2017-09-15 プロスタサイクリン類似体製剤

Country Status (17)

Country Link
US (3) US11369617B2 (enExample)
EP (1) EP3512495B1 (enExample)
JP (1) JP7527785B2 (enExample)
KR (1) KR20190083645A (enExample)
CN (1) CN109715138B (enExample)
AU (1) AU2017328630B2 (enExample)
CA (1) CA3036307A1 (enExample)
DK (1) DK3512495T3 (enExample)
ES (1) ES2933175T3 (enExample)
IL (1) IL265270B (enExample)
LT (1) LT3512495T (enExample)
MX (1) MX390136B (enExample)
PL (1) PL3512495T3 (enExample)
PT (1) PT3512495T (enExample)
RU (1) RU2757903C2 (enExample)
SI (1) SI3512495T1 (enExample)
WO (1) WO2018050864A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109150387B (zh) 2017-06-16 2023-04-28 华为技术有限公司 发送参考信号的方法、接收参考信号的方法和通信装置
WO2020240018A1 (en) 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
JP7542661B2 (ja) * 2020-06-30 2024-08-30 チョン クン ダン ファーマシューティカル コーポレーション Ｇｎｒｈ誘導体を含む注射用組成物
MX2023003506A (es) * 2020-09-25 2023-06-28 Algorithm Sciences Inc Composiciones y métodos para la administración de vasodilatadores.
WO2024107096A1 (en) * 2022-11-14 2024-05-23 Camurus Ab Treprostinil formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501676A (ja) 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008526934A (ja) 2005-01-14 2008-07-24 カムルス エービー ＧｎＲＨ類似体製剤
JP2014522878A (ja) 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2014527050A (ja) 2011-08-12 2014-10-09 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
JP2016504352A (ja) 2012-12-28 2016-02-12 チョン クン ダン ファーマシューティカル コーポレーション アニオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125255A1 (de) 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
AU7343894A (en) 1993-07-28 1995-02-28 University Of Saskatchewan Biphasic multilamellar lipid vesicles
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
CA2959852A1 (en) * 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
CN101090714A (zh) * 2004-07-26 2007-12-19 康泽里克斯公司 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
KR102066755B1 (ko) 2011-05-25 2020-01-15 카무러스 에이비 조절 방출형 펩티드 제형
WO2013038460A1 (ja) 2011-09-16 2013-03-21 株式会社日立製作所 画像表示システム及びその方法
AU2012348640B2 (en) * 2011-12-05 2016-07-21 Camurus Ab Robust controlled-release peptide formulations
PL2877155T3 (pl) * 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
WO2014085813A1 (en) * 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501676A (ja) 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008526934A (ja) 2005-01-14 2008-07-24 カムルス エービー ＧｎＲＨ類似体製剤
JP2014522878A (ja) 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2014527050A (ja) 2011-08-12 2014-10-09 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
JP2016504352A (ja) 2012-12-28 2016-02-12 チョン クン ダン ファーマシューティカル コーポレーション アニオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物

Also Published As

Publication number Publication date
CN109715138A (zh) 2019-05-03
LT3512495T (lt) 2022-12-27
EP3512495A1 (en) 2019-07-24
RU2019108832A3 (enExample) 2020-11-30
MX2019002999A (es) 2019-07-18
ES2933175T3 (es) 2023-02-02
AU2017328630B2 (en) 2020-06-18
IL265270A (en) 2019-05-30
US20250319097A1 (en) 2025-10-16
AU2017328630A1 (en) 2019-04-11
RU2757903C2 (ru) 2021-10-22
US20190255068A1 (en) 2019-08-22
US20220387445A1 (en) 2022-12-08
CA3036307A1 (en) 2018-03-22
US11369617B2 (en) 2022-06-28
PL3512495T3 (pl) 2023-01-23
RU2019108832A (ru) 2020-10-15
DK3512495T3 (da) 2022-12-05
EP3512495B1 (en) 2022-11-09
PT3512495T (pt) 2023-02-15
WO2018050864A1 (en) 2018-03-22
MX390136B (es) 2025-03-20
SI3512495T1 (sl) 2023-01-31
CN109715138B (zh) 2022-06-28
KR20190083645A (ko) 2019-07-12
JP2019529408A (ja) 2019-10-17
IL265270B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20250319097A1 (en) Prostacyclin analogue formulations
US12396944B2 (en) Injectable buprenorphine formulation
US20140378381A1 (en) Stabilized glucagon nanoemulsions
US20080146490A1 (en) Glp-1 Analogue Formulations
HK1217440A1 (zh) 含酸的脂质制剂
KR20140049090A (ko) 펩티드 서방형 제형
US20180256496A1 (en) Controlled-release formulations
JP6417327B2 (ja) オピオイド製剤
RS61377B1 (sr) Opioidne formulacije
JP2024026333A (ja) 持続放出ペプチド製剤
WO2024107096A1 (en) Treprostinil formulations
RU2833056C2 (ru) Составы на основе пептидов с длительным высвобождением

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220916

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221027

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221101

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221111

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7527785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150